Médecine

Paramédical

Autres domaines


S'abonner

Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: A prospective, cross-sectional study - 12/04/19

Doi : 10.1016/j.jaad.2018.12.051 
Elana Putterman, BS a, Deepa P. Patel, MD a, Gabriela Andrade, MD a, Katya L. Harfmann, MD b, Marcia Hogeling, MD c, Carol E. Cheng, MD c, Carolyn Goh, MD c, Rachel S. Rogers, MS d, Leslie Castelo-Soccio, MD, PhD a, e,
a Division of Pediatrics, Section of Dermatology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 
b Department of Dermatology, Nationwide Children's Hospital, Columbus, Ohio 
c Division of Dermatology, University of California Los Angeles, Los Angeles, California 
d Biostatistics and Data Management, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 
e University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 

Correspondence to: Leslie Castelo-Soccio, MD, PhD, Division of Pediatrics, Section of Dermatology, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd, The Richard Wood Pediatric Ambulatory Care Center, Rm 3335, Philadelphia, PA 19104.Division of PediatricsSection of DermatologyThe Children's Hospital of Philadelphia3401 Civic Center BlvdThe Richard Wood Pediatric Ambulatory Care CenterRm 3335PhiladelphiaPA19104

Abstract

Background

Caregiver-oriented quality of life (QoL) research in alopecia areata is limited. No study has used a parent-tailored survey to examine the relationship between QoL and severity of alopecia as measured by Severity of Alopecia Tool (SALT) scores.

Objectives

This is a prospective study that describes QoL in parents of pediatric patients with all subtypes of alopecia areata and investigates the relationship between QoL and severity of disease, duration of disease, and age of patients.

Methods

Pediatric patients and their parents were invited to participate during clinic visits. Participating parents completed the Quality of Life in a Child's Chronic Disease Questionnaire (QLCCDQ) and the Family Dermatology Life Quality Index (FDLQI). A subset of children completed the Children's Dermatologic Life Quality Index (CDLQI). SALT scores at time of survey completion were recorded.

Results

In total, 153 patients were included. Significant mild-to-moderate negative correlations were found between SALT scores and FDLQI scores, QLCCDQ scores, and QLCCDQ emotional domain scores. Age of child correlated negatively with QLCCDQ scores but not FDLQI scores. No significant correlation was found between duration of disease and FDLQI scores, QLCCDQ scores, or QLCCDQ emotional domain scores.

Limitations

This study is limited by its small sample size and cross-sectional design.

Conclusions

Impaired parent QoL might be associated with increasing severity of disease and age of affected child but not duration of disease. Providers should tailor counseling accordingly and help parents set realistic expectations for long-term experience with the disease.

Le texte complet de cet article est disponible en PDF.

Key words : alopecia areata, alopecia totalis, alopecia universalis, hair loss, Severity of Alopecia Tool, quality of life

Abbreviations used : AA, AT, AU, CDLQI, FDLQI, QLCCDQ, QoL, SALT, SD


Plan


 Funding sources: Supported by a Pediatric Dermatologic Research Alliance grant awarded to the authors at the Children's Hospital of Philadelphia.
 Conflicts of interest: None disclosed.
 Reprints not available from the authors.


© 2019  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 80 - N° 5

P. 1389-1394 - mai 2019 Retour au numéro
Article précédent Article précédent
  • The diagnostic accuracy of dermoscopy for basal cell carcinoma: A systematic review and meta-analysis
  • Ofer Reiter, Ilit Mimouni, Michael Gdalevich, Ashfaq A. Marghoob, Assi Levi, Emmilia Hodak, Yael Anne Leshem
| Article suivant Article suivant
  • Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial
  • Sonja Ständer, Paul Kwon, Joe Hirman, Andrew J. Perlman, Elke Weisshaar, Martin Metz, Thomas A. Luger, TCP-102 Study Group

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement ou un achat à l’unité.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.